Analysts Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Price Target at $24.77

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been given an average recommendation of “Hold” by the twenty-seven analysts that are presently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a sell recommendation, thirteen have assigned a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $24.7727.

SRPT has been the topic of a number of analyst reports. Jefferies Financial Group reissued a “buy” rating and issued a $30.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, March 3rd. HC Wainwright reissued a “sell” rating on shares of Sarepta Therapeutics in a research report on Thursday, April 16th. Royal Bank Of Canada boosted their price target on Sarepta Therapeutics from $18.00 to $19.00 and gave the stock a “sector perform” rating in a research report on Tuesday, April 7th. Citigroup boosted their price target on Sarepta Therapeutics from $9.00 to $13.00 and gave the stock a “sell” rating in a research report on Thursday, March 26th. Finally, Needham & Company LLC reissued an “underperform” rating on shares of Sarepta Therapeutics in a research report on Thursday, March 26th.

Sarepta Therapeutics Price Performance

SRPT stock opened at $15.31 on Wednesday. Sarepta Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $38.09. The business’s 50 day moving average price is $19.23 and its two-hundred day moving average price is $19.75. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.62 and a current ratio of 4.63. The company has a market capitalization of $1.62 billion, a price-to-earnings ratio of -15.95, a price-to-earnings-growth ratio of 0.16 and a beta of 0.21.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $2.18. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The firm had revenue of $730.80 million for the quarter, compared to analysts’ expectations of $474.16 million. During the same period in the previous year, the firm posted ($3.42) EPS. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. As a group, analysts forecast that Sarepta Therapeutics will post 3.99 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its position in Sarepta Therapeutics by 26.6% in the 1st quarter. Bank of America Corp DE now owns 2,145,926 shares of the biotechnology company’s stock valued at $46,695,000 after acquiring an additional 450,336 shares in the last quarter. Bull Harbor Capital LLC bought a new position in Sarepta Therapeutics in the 1st quarter valued at approximately $398,000. ADAR1 Capital Management LLC lifted its position in Sarepta Therapeutics by 807.8% in the 1st quarter. ADAR1 Capital Management LLC now owns 262,058 shares of the biotechnology company’s stock valued at $5,702,000 after acquiring an additional 233,192 shares in the last quarter. California State Teachers Retirement System lifted its position in Sarepta Therapeutics by 27.6% in the 1st quarter. California State Teachers Retirement System now owns 120,686 shares of the biotechnology company’s stock valued at $2,626,000 after acquiring an additional 26,141 shares in the last quarter. Finally, Royal Bank of Canada lifted its position in Sarepta Therapeutics by 2.3% in the 1st quarter. Royal Bank of Canada now owns 222,850 shares of the biotechnology company’s stock valued at $4,849,000 after acquiring an additional 5,088 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.